MAY 0 4 2005 &

PTO/SB/08A (08-03) Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

+

Under the Reperwork Reduction control number 4

Sheet

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known			
Application Number	09/913,443		
Filing Date	August 14, 2001		
First Named Inventor	Jack Price		
Art Unit	1636		
Examiner Name	Celine X. Qian		
Attorney Docket Number	GIE-74		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
a	U <u>1</u>	US-5,588,692	11-18-1997	Jat et al.	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			•
	U9	US-			

		FOREIGN	PATENT DOC	UMENTS		
	T	Foreign Patent Document	D. Miller No. Bada	Name of Batastan as	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	14
	Cite No. '	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
	F1					L
	F2					<u> </u>
	F3					_
	F4					
	F5					
	F6					<u> </u>
	F7				i	

Examiner	Date	71 - 1
Signature	Considered	1/23/5

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Under the Paneawork Rec

Sheet

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Complete if Known			
Application Number	09/913,443		
Filing Date	August 14, 2001		
First Named Inventor	Jack Price		
Group Art Unit	1636		
Examiner Name	Celine X. Qian		
Attorney Docket Number	GJE-74		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	ite Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the		
CCL R1		COGLE, C.R. et al. "Bone marrow transdifferentiation in brain after transplantation: a retrospective study" Lancet, 2004, 363(9419):1432-1437, abstract.		
_	R2	DAADI, M.M. and S. WEISS "Generation of tyrosine hydroxylase-producing neurons from precursors of tembryonic and adult forebrain" <i>J. Neuroscience</i> , 1999, 19(11):4484-4497.		
	R3	EGLITIS, M. and E. MEZEY "Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice" <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94:4080-4085.		
	R4	GOOLSBY, J. et al. "Hematopoietic progenitors express neural genes" PNAS, 2003, 100(25):14926-14931.		
	R5	HAO, H.N. et al. "Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes in vitro" J. Hematother Stem Cell Res., 2003, 12(1):23-32.		
	R6	HESS, D.C. et al. "Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke" Stroke, 2002, 33:1362-1368.		
	R7	JAT, P.S. et al. "Direct derivation of conditionally immortal cell lines from an H-2K*-tsA58 transgenic mouse" Proc. Natl. Acad. Sci. USA, 1991, 88:5096-5100.		
	R8	JAT, P. and SHARP, P. "Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature" Mol. Cell. Biology, 1989, 9(4):1672-1681.		
	R9	KOSHIZUKA, S. et al. "Transplanted hematopoietic stem cells from bone marrow differentiate into neural lineage cells and promote functional recovery after spinal cord injury in mice" J. Neuropath. Exp. Neurology, 2004, 63(1):64-72.		
	R10	PRILLER, J. "Can adult bone marrow stem cells help repair the brain?" ACNR, 2004, 3(6):11-13.		
	R11	PRILLER, J. et al. "Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment" Nature Med., 2001, 7(12):1356-1361.		
	R12			
	K12			
	R13		<u> </u>	

Examiner Signature	flee	Date Considered	1/13/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.